Blog
RSS FeedPosted by Michael Wonder on 07 May 2026
Diakonos Oncology awarded fast track designation by FDA for DOC1021 (dubodencel) in unresectable or metastatic cutaneous melanoma
6 May 2026 - Diakonos Oncology announced today that the US FDA has granted fast track designation to DOC1021, the ...
Posted by Michael Wonder on 06 May 2026
ICER publishes protocol for annual launch price and access report
4 May 2026 - The ICER posted a protocol today outlining how it will conduct its second annual analysis titled the ...
Posted by Michael Wonder on 06 May 2026
Healyth Canada authorised Lilly's Kisunla (donanemab), a new treatment for early Alzheimer's disease
4 May 2026 - Today, after more than 35 years of commitment to advancing Alzheimer's research, Lilly Canada announced Health Canada's ...
Posted by Michael Wonder on 06 May 2026
Norgine welcomes TGA registration in Australia of Pedmarqsi (sodium thiosulphate anhydrous) for the prevention of cisplatin-induced hearing loss in children
6 May 2026 - Norgine is pleased to announce that Pedmarqsi (sodium thiosulphate anhydrous) has been registered by the Australian TGA ...
Posted by Michael Wonder on 05 May 2026
FDA grants fast track designation for CS-1103, a first in class small molecule to reverse acute intoxication from fentanyl
5 May 2026 - Clear Scientific announced today that the US FDA has granted its lead asset, CS-1103, fast track designation ...
Posted by Michael Wonder on 05 May 2026
Spinogenix receives US FDA fast track designation for tazbentetol for the treatment of ALS
5 May 2026 - Spinogenix today announced that the US FDA has granted fast track designation to tazbentetol for the ...
Posted by Michael Wonder on 05 May 2026
Satellite Bio announces FDA rare paediatric disease designation for SB-101 for the treatment of urea cycle disorders
4 May 2026 - Satellite Biosciences today announced that the US FDA has granted rare paediatric disease designation for SB-101 for ...
Posted by Michael Wonder on 05 May 2026
Expert says treatment relieves children's suffering and saves hospital resources
5 May 2026 - The family of an eight year old Sunshine Coast girl is petitioning the federal government to ...
Posted by Michael Wonder on 05 May 2026
Atossa Therapeutics receives FDA rare paediatric disease designation for (Z)-endoxifen for McCune-Albright syndrome
4 May 2026 - Atossa Therapeutics today announced that the US FDA has granted rare paediatric disease designation to (Z)-endoxifen for ...
Posted by Michael Wonder on 04 May 2026
'Tearing her skin apart': Sydney family among thousands priced out of life-changing medication
3 May 2026 - Jade Hlucshniow was on the brink of selling her home to afford treatment for her daughter, ...
Posted by Michael Wonder on 04 May 2026
Korea covers Takeda’s Takhzyro, but most patients may still be left out: experts
26 March 2026 - Korea has granted reimbursement for Takeda’s hereditary angioedema drug Takhzyro (lanadelumab), but physicians say most patients ...
Posted by Michael Wonder on 04 May 2026
New first in class therapy for chronic graft versus host disease approved in Australia
3 May 2026 - Specialised Therapeutics is pleased to announce that Niktimvo (axatilimab) has been approved for use in Australia ...
Posted by Michael Wonder on 03 May 2026
Affordable treatment for Australians with colorectal cancer
3 May 2026 - Australians with stage 4 colorectal cancer are among those who will benefit from new drug listings ...
Posted by Michael Wonder on 03 May 2026
US pushes real time clinical trials to eliminate “dead time” in approvals
1 May 2026 - The US FDA is testing “real time clinical trials,” which it says will provide faster access ...
Posted by Michael Wonder on 03 May 2026
Apotex becomes the first Canadian‑based pharmaceutical company to receive Health Canada approval for a generic equivalent of Ozempic
1 May 2026 - Apotex today announced that Health Canada has approved Apo‑Semaglutide Injection, a generic equivalent of Ozempic (semaglutide injection). ...